Masato Ozaka

11PUBLICATIONS
61CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursSolid tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Sep 19, 2026
Association between ABCB1 genetic polymorphisms with treatment outcomes in patients with metastatic pancreatic cancer.

|Aug 28, 2026
Influence of LGALS3 polymorphisms on chemotherapy-induced peripheral neuropathy in patients with metastatic pancreatic cancer treated with gemcitabine and nab-paclitaxel: an exploratory biomarker analysis of the GENESECT study.

|Feb 27, 2026
Impact of Hepatitis B Virus Infection on the Efficacy and Safety of Pembrolizumab plus Chemotherapy for Advanced Biliary Tract Cancer in the KEYNOTE-966 Study.

Stephen L Chan, Thomas Yau, Robin K Kelley

|Jul 28, 2025
Modified Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin or S-1, Irinotecan, and Oxaliplatin Versus Nab-Paclitaxel + Gemcitabine in Metastatic or Recurrent Pancreatic Cancer (GENERATE, JCOG1611): A Randomized, Open-Label, Phase II/III Trial.

Akihiro Ohba, Masato Ozaka, Junki Mizusawa

|Jun 11, 2025
Impact of second-line combination chemotherapy on post-progression survival in metastatic and recurrent pancreatic cancer.

Takafumi Mie, Masato Ozaka, Takeshi Okamoto

|Apr 10, 2025
Pathological complete response following addition of durvalumab to gemcitabine and cisplatin therapy for intrahepatic cholangiocarcinoma with Lynch syndrome-associated mismatch repair deficiency.

Koshiro Fukuda, Akiyoshi Kasuga, Yasuyuki Shigematsu

Pageof 2

Frequent Collaborators

5 joint publications

Naoki Sasahira

3 joint publications

Takeshi Okamoto

3 joint publications

Akiyoshi Kasuga

3 joint publications

Makoto Ueno